Pepinemab is a humanized monoclonal IgG4 antibody designed to block the signaling activity of semaphorin 4D (SEMA4D). This innovative therapeutic targets the underlying mechanisms of cancer progression and neurodegenerative diseases, offering a potential new approach to treatment.